Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00190970 · ClinicalTrials.gov registry record · Phase 2
The Effect of Ruboxistaurin on Small Fiber Function
A Phase 2 study of Diabetic Neuropathy, sponsored by Chromaderm.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT00190970: Completed Phase 2 study of Diabetic Neuropathy, sponsored by Chromaderm.
NCT00190970 is a Phase 2 study of Diabetic Neuropathy that has completed, run by Chromaderm. The registered enrollment target is 52 participants, below the 178-participant average among 8 other Diabetic Neuropathy trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00190970, a Phase 2 study of Diabetic Neuropathy, has completed, sponsored by Chromaderm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the effect of Ruboxistaurin on small fiber function.
Conditions Studied
Interventions
- DRUG Ruboxistaurin
Study Locations (1)
Virginia
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2004-10 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
What the finished NCT00190970 record still lists
NCT00190970 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 178-participant average among 8 other Diabetic Neuropathy trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Diabetic Neuropathy appearing as the primary indexed condition, and to 1 intervention - of which Ruboxistaurin is the first listed.
NCT00190970 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT00190970 about?
NCT00190970 is a clinical study titled "The Effect of Ruboxistaurin on Small Fiber Function". To determine the effect of Ruboxistaurin on small fiber function.
What is the current status of trial NCT00190970?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2004-10. Estimated completion is 2005-11.
What conditions does trial NCT00190970 study?
This clinical trial studies the following conditions: Diabetic Neuropathy.
What interventions are being tested in trial NCT00190970?
The interventions under investigation include: Ruboxistaurin (DRUG).
Who is sponsoring clinical trial NCT00190970?
This trial is sponsored by Chromaderm, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00190970 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00190970's enrollment target sits among peer trials
52 9th of 8 the lowest of 8 other Diabetic Neuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Neuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy
COMPLETED · Phase 2
-
Study of DA-9801 to Treat Diabetic Neuropathy
COMPLETED · Phase 2
-
The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy
COMPLETED · Phase 2
-
Clinical Outcomes Related to Treatment of Distal Symmetric Polyneuropathy Using Semiconductor Embedded Therapeutic Socks
RECRUITING · NA
-
Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project
ACTIVE NOT RECRUITING
-
Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia